Advertisement

 

 

Bone Markers as Screening Strategy for Patient Adherence to Osteoporosis Medications

Bone Markers as Screening Strategy for Patient Adherence to Osteoporosis Medications
Author Information (click to view)

International Osteoporosis Foundation


International Osteoporosis Foundation (click to view)

International Osteoporosis Foundation

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

A new position paper proposes measuring specific bone turnover markers (BTMs) in patients who have initiated use of oral bisphosphonates for postmenopausal osteoporosis as a practical way to identify low adherence.

Oral bisphosphonates are common first line treatments for osteoporosis. However, approximately half of patients who begin osteoporosis treatment do not follow their prescribed treatment and/or discontinue treatment within a year. Identifying low adherence to medication – a problem commonly seen with many chronic diseases – is a critical issue as it jeopardizes the efficacy of treatment, leaving osteoporosis patients unprotected against fractures.

A newly published International Osteoporosis Foundation (IOF) and European Calcified Tissue Society (ECTS) Working Group position paper proposes measuring specific bone turnover markers (BTMs) in patients who have initiated use of oral bisphosphonates for postmenopausal osteoporosis as a clinically feasible and practical way to identify low adherence. BTMs can reflect the early effect of the drug on bone tissue. If a low response is detected shortly after treatment has been started, this can indicate low adherence or point to underlying causes of impaired response to medication.


Related Articles


Using the findings of the TRIO study [2] as the basis for their recommendations, the Working Group recommends measuring serum PINP (procollagen type 1 N-terminal propeptide) and CTX (collagen type 1 C-terminal telopeptide) levels at baseline and after 3 months of initiating treatment. The timing for the assessment at 3 months is optimal because the first weeks after the prescription is given is the critical period of primary non-adherence, when patients are most likely to have discontinued treatment.

Read the press release here.

Submit a Comment

Your email address will not be published. Required fields are marked *

2 × three =

[ HIDE/SHOW ]